Year-end report January-December 2024 CombiGene AB (Publ)
October – December 2024
- Net sales: 0 (596) TSEK.
- Other operating income: 1,962 (875) TSEK.
- Result after financial items: -14,157 (-6,360) TSEK.
- Earnings per share: -0.71 SEK (-0.32).
January – December 2024
- Net sales: 326 (5,544) TSEK.
- Other operating income: 3,274 (1,464) TSEK.
- Result after financial items: -44,878 (-35,665) TSEK.
- Earnings per share: -2.27 SEK (-1.80).
- Cash and cash equivalents at the end of the period: 73,748 (101,440) TSEK.
Events during the fourth quarter of 2024
• CombiGene initiates measures to extend the liquidity horizon by sharpening the strategic focus on gene therapy, prioritizing pipeline assets, and implementing a cost reduction program.
• CombiGene holds an extraordinary general meeting. The meeting decided, in accordance with the shareholder Strategic Partner A/S’s proposal, that the board should consist of three ordinary board members with one deputy board member. Luca Di Stefano and Jakob Bendtsen were elected, and Marcus Isaksson was re-elected, as board members. Furthermore, Lars Thunberg was elected as a new deputy board member.
The meeting also decided, in accordance with the shareholder Strategic Partner A/S’s proposal, to amend the articles of association. The amendment was made to expand the business purpose, allowing the company to enter strategic partnerships with other companies in other industries.
Events after the end of the period
• CombiGene AB initiates restructuring as part of a strategic review to maximize shareholder value and terminates all employment, including the CEO. The severance cost for the staff is estimated to amount to approximately SEK 6.8 million.
• CombiGene AB discontinues all activities and collaborations linked to research. The winding-up cost for operations and projects is estimated to amount to SEK 0.9 million.